REVEAL Study: Accurate Diagnosis of Cardiac Amyloidosis

Diagnosing myocardial infiltration early remains a critical clinical challenge in heart failure care. Fortunately, advanced cardiac amyloidosis PET CT imaging using the novel pan-amyloid radiotracer 124I-evuzamitide addresses this diagnostic gap. The multicenter REVEAL clinical trial evaluated this pan-fibril targeting agent in patients undergoing diagnostic evaluation for suspected cardiac amyloidosis.

High Accuracy of Cardiac Amyloidosis PET CT

Historically, standard bone scintigraphy primarily detects transthyretin amyloid cardiomyopathy but misses light-chain forms. In contrast, 124I-evuzamitide binds directly to amyloid fibrils across diverse systemic amyloid subtypes. Consequently, investigators designed the prospective REVEAL trial across 18 centers in the United States. The trial enrolled 170 adult participants presenting with heart failure symptoms and suspected cardiac involvement. Blind expert panels assessed myocardial tracer uptake alongside standard-of-care clinical diagnostic criteria. Specifically, visual PET scan analysis achieved an outstanding overall diagnostic sensitivity of 94%. Furthermore, the radiotracer demonstrated a robust diagnostic specificity of 97% across all evaluated cohorts.

Clinical Implications for Practice

Accurate diagnosis early in the disease course alters patient trajectories significantly. Therefore, noninvasive whole-body imaging eliminates the routine requirement for invasive myocardial tissue biopsy. Additionally, the tracer provides clear visualization of extracardiac organ involvement in systemic amyloidosis. Moreover, researchers observed favorable safety profiles without significant radiotracer-related adverse drug events. Ultimately, this targeted molecular imaging approach will accelerate timely initiation of disease-modifying therapies.

Frequently Asked Questions

Q1: What is the primary diagnostic benefit of 124I-evuzamitide?

Unlike bone scintigraphy tracers that selectively identify transthyretin amyloidosis, 124I-evuzamitide detects both light-chain and transthyretin amyloid fibrils across cardiac and extracardiac tissues.

Q2: What were the key diagnostic performance metrics in the REVEAL trial?

The REVEAL clinical trial demonstrated a 94% diagnostic sensitivity and a 97% specificity for identifying cardiac amyloidosis using visual scan interpretation.

Q3: How does this PET imaging agent affect patient management?

This noninvasive molecular imaging agent facilitates early diagnostic confirmation, reduces the need for invasive endomyocardial biopsy, and supports prompt therapeutic intervention.

References

1. Dorbala S et al. 124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial. JAMA. 2026 Aug 30. doi: 10.1001/jama.2026.17361. PMID: 42669054.
2. Masri A et al. 124I-Evuzamitide PET Imaging for the Detection of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2026. doi: 10.1016/j.jcmg.2026.08.012.